Evaluation of a Breast Cancer Survivorship Programme: 7-year patient outcomes and service experience
Association of Breast Surgery ePoster Library. Edwards K. 05/13/19; 257086; P042
Kimberley Edwards
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P042
Topic: Breast surgery
Introduction: In 2018, the National Institute of Clinical Excellence published new guidance on the follow-up of early breast cancer on completion of initial treatment, reflecting a move from traditional follow-up, with increased focus on supporting holistic needs and developing an individual approach. Prior to this, the National Cancer Survivorship Initiative (NCSI) was established to prototype pathways of care for cancer survivors. This evaluation considers data gathered by Hull and East Yorkshire NHS Trust over 7 years as an NCSI vanguard, to examine the safety of the survivorship programme and to discuss our experience. Methods 12 months from curative surgery for primary breast cancer, patients received a surveillance mammogram and consultant surgeon review, followed by holistic needs assessment with a breast care nurse. Suitable patients received annual surveillance mammography for a subsequent 3 years with a final mammogram and consultant surgeon review at year 5. Results: Prospectively gathered data from a sample of 436 consecutive patients entered into the programme during the first 2 operational years (2010-2012) is considered. 86%(n=374) completed the programme without disease recurrence. 9%(n=42) developed loco-regional recurrence, contralateral primary or metastatic disease. 66% required no unplanned clinical review. 150 patients (206 attendances) required additional review: 37% with endocrine therapy side effects, 21% with suspected breast lumps and 12% with back/bone pain, yet only 10%(n=20) of appointments confirmed disease recurrence. ConclusionsOur survivorship programme is a safe method of delivering follow-up care, demonstrating significant improvement in usage of outpatient resources whilst empowering breast cancer survivors.
Topic: Breast surgery
Introduction: In 2018, the National Institute of Clinical Excellence published new guidance on the follow-up of early breast cancer on completion of initial treatment, reflecting a move from traditional follow-up, with increased focus on supporting holistic needs and developing an individual approach. Prior to this, the National Cancer Survivorship Initiative (NCSI) was established to prototype pathways of care for cancer survivors. This evaluation considers data gathered by Hull and East Yorkshire NHS Trust over 7 years as an NCSI vanguard, to examine the safety of the survivorship programme and to discuss our experience. Methods 12 months from curative surgery for primary breast cancer, patients received a surveillance mammogram and consultant surgeon review, followed by holistic needs assessment with a breast care nurse. Suitable patients received annual surveillance mammography for a subsequent 3 years with a final mammogram and consultant surgeon review at year 5. Results: Prospectively gathered data from a sample of 436 consecutive patients entered into the programme during the first 2 operational years (2010-2012) is considered. 86%(n=374) completed the programme without disease recurrence. 9%(n=42) developed loco-regional recurrence, contralateral primary or metastatic disease. 66% required no unplanned clinical review. 150 patients (206 attendances) required additional review: 37% with endocrine therapy side effects, 21% with suspected breast lumps and 12% with back/bone pain, yet only 10%(n=20) of appointments confirmed disease recurrence. ConclusionsOur survivorship programme is a safe method of delivering follow-up care, demonstrating significant improvement in usage of outpatient resources whilst empowering breast cancer survivors.
P042
Topic: Breast surgery
Introduction: In 2018, the National Institute of Clinical Excellence published new guidance on the follow-up of early breast cancer on completion of initial treatment, reflecting a move from traditional follow-up, with increased focus on supporting holistic needs and developing an individual approach. Prior to this, the National Cancer Survivorship Initiative (NCSI) was established to prototype pathways of care for cancer survivors. This evaluation considers data gathered by Hull and East Yorkshire NHS Trust over 7 years as an NCSI vanguard, to examine the safety of the survivorship programme and to discuss our experience. Methods 12 months from curative surgery for primary breast cancer, patients received a surveillance mammogram and consultant surgeon review, followed by holistic needs assessment with a breast care nurse. Suitable patients received annual surveillance mammography for a subsequent 3 years with a final mammogram and consultant surgeon review at year 5. Results: Prospectively gathered data from a sample of 436 consecutive patients entered into the programme during the first 2 operational years (2010-2012) is considered. 86%(n=374) completed the programme without disease recurrence. 9%(n=42) developed loco-regional recurrence, contralateral primary or metastatic disease. 66% required no unplanned clinical review. 150 patients (206 attendances) required additional review: 37% with endocrine therapy side effects, 21% with suspected breast lumps and 12% with back/bone pain, yet only 10%(n=20) of appointments confirmed disease recurrence. ConclusionsOur survivorship programme is a safe method of delivering follow-up care, demonstrating significant improvement in usage of outpatient resources whilst empowering breast cancer survivors.
Topic: Breast surgery
Introduction: In 2018, the National Institute of Clinical Excellence published new guidance on the follow-up of early breast cancer on completion of initial treatment, reflecting a move from traditional follow-up, with increased focus on supporting holistic needs and developing an individual approach. Prior to this, the National Cancer Survivorship Initiative (NCSI) was established to prototype pathways of care for cancer survivors. This evaluation considers data gathered by Hull and East Yorkshire NHS Trust over 7 years as an NCSI vanguard, to examine the safety of the survivorship programme and to discuss our experience. Methods 12 months from curative surgery for primary breast cancer, patients received a surveillance mammogram and consultant surgeon review, followed by holistic needs assessment with a breast care nurse. Suitable patients received annual surveillance mammography for a subsequent 3 years with a final mammogram and consultant surgeon review at year 5. Results: Prospectively gathered data from a sample of 436 consecutive patients entered into the programme during the first 2 operational years (2010-2012) is considered. 86%(n=374) completed the programme without disease recurrence. 9%(n=42) developed loco-regional recurrence, contralateral primary or metastatic disease. 66% required no unplanned clinical review. 150 patients (206 attendances) required additional review: 37% with endocrine therapy side effects, 21% with suspected breast lumps and 12% with back/bone pain, yet only 10%(n=20) of appointments confirmed disease recurrence. ConclusionsOur survivorship programme is a safe method of delivering follow-up care, demonstrating significant improvement in usage of outpatient resources whilst empowering breast cancer survivors.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}